GoodRx (Nasdaq: GDRX) announced it is working with ARS Pharmaceuticals to offer the lowest discounted cash price for neffy in ...

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS ...

ARS Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) for a1 mg dose of nasal spray neffy, to treat type 1 emergency allergic reactions in children weighing 33 to 66 lbs., ...

(MENAFN- GlobeNewsWire - Nasdaq) If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1 mg sNDA ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

The revenue for Neffy is expected to reach an annual total of $722 mn by 2033 in the US based off GlobalData s Expiry Model. The drug s revenue forecasts along with estimated costs are used to measure ...

It’s called Neffy and it’s an epinephrine nasal spray. Epinephrine is the only life-saving treatment for anaphylaxis and, until now, was administered via a needle in an auto-injector like the ...

ARS Pharmaceuticals' neffy, a needle-free nasal spray for Type I allergic reactions, received early FDA approval, driving a 120% YTD share price increase. Neffy addresses a significant unmet need ...

She also brings valuable board experience from her roles at Vital Farms, RAD Power Bikes, and GoodRx. Ms. Kennedy's deep understanding of the financial services sector, combined with her ...

Investors tracking insider transactions at GoodRx Holdings, Inc. (NASDAQ:GDRX) may note recent activity where Spectrum Equity entities sold shares in the company. The transactions were executed at ...

neffy 2 mg is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater. IMPORTANT SAFETY INFORMATION It is ...

Pre-ordering for epinephrine nasal spray (neffy; ARS Pharmaceuticals) to treat type 1 of allergic reactions, including anaphylaxis, in adult and pediatric patients who weight at least 66 pounds (30 ...